News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Balance sheet
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
aTyr Pharma's stock rose 1.8% in pre-open trading after announcing better-than-expected second-quarter results and a significant operational restructuring. The company reported a narrower loss per share, a 60% workforce reduction, and a focused pipeline on its lead candidate, efzofitimod, for interstitial lung disease. Investors …
(RTTNews) - aTyr Pharma, Inc. (ATYR) announced second-quarter 2026 results and prioritised a corporate restructuring involving a 60% workforce reduction to advance its lead therapeutic candidate, Efzofitimod, in interstitial lung disease (ILD). aTyr's lead therapeutic candidate, efzofitimod, is a biologic immunomodulator in clinical development …
Levi & Korsinsky LLP has issued a securities lawsuit alert for investors of aTyr Pharma, Inc. (NASDAQ:ATYR). The alert concerns a class action lawsuit filed against aTyr Pharma, Inc. seeking to recover losses for shareholders who were adversely affected by alleged securities fraud between …
aTyr Pharma is laying off 60% of its workforce to conserve resources for a second attempt at phase 3 success for its lung disease drug, efzofitimod. The company is awaiting FDA feedback on a new phase 3 study protocol after the drug missed its …
This article announces ATyr Pharma's second quarter 2026 results. The content is currently a placeholder and does not contain detailed financial information or a full report.
aTyr Pharma (ATYR) reported a reduced net loss of $(10.3M) and an EPS of $(0.11) for Q2 2026, primarily due to lower research-and-development spending. The company plans to initiate a new global Phase 3 study for pulmonary sarcoidosis despite its EFZO-FIT trial missing its …
aTYR Pharma reported a Q2 2026 net loss of $10.3 million and ended the quarter with $58.9 million in cash. The company is implementing a corporate restructuring, including a 60% workforce reduction, to conserve capital and focus on its lead candidate efzofitimod for interstitial …
aTyr Pharma Inc (NASDAQ: ATYR) announced its Q2 financial results and a major strategic restructuring, including a 60% workforce reduction, to prioritize its efzofitimod program for interstitial lung diseases. Despite an extremely high Price-to-Sales ratio of 255.7x and ongoing unprofitability, the company is preparing …
A class action securities lawsuit has been filed against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that the company made false and misleading statements regarding the efficacy of its …
ATyr Pharma reported a narrower fiscal Q2 loss. The company also announced restructuring plans, with further details provided in the last three paragraphs of the article. Access to the full MT Newswires article requires a premium subscription.
FMR LLC and Abigail P. Johnson have reported a 2.5% passive ownership stake in ATYR Pharma Inc. This disclosure, made via an amended Schedule 13G, indicates that FMR LLC beneficially owns 2,471,418 shares, with sole voting power over 2,464,141 shares and sole dispositive power …
Levi & Korsinsky LLP has filed a class action securities lawsuit against aTyr Pharma, Inc. (ATYR) on behalf of shareholders who suffered losses between November 7, 2024, and September 12, 2025. The lawsuit alleges that aTyr Pharma made false and misleading statements regarding the …
A class action lawsuit has been filed against aTyr Pharma, Inc. (ATYR) alleging securities fraud between November 7, 2024, and September 12, 2025. The lawsuit claims the company made misleading statements regarding the efficacy of its drug Efzofitimod, particularly its ability to reduce steroid …
MarketScreener has withdrawn alerts regarding Ethos Technologies' Q2 results that were erroneously attributed to aTyr Pharma, Inc. The original publication was made on August 3, 2026, at 04:48 pm EDT by Reuters. This correction highlights a data misattribution concerning financial reporting.
aTyr Pharma Inc is projected to report a loss of 12 cents per share, according to an earnings preview. This information is sourced from Refinitiv and was published by Reuters. The full article is available on TradingView, which aggregates news from various sources.
aTyr Pharma Inc (ATYR) currently holds a financial score of 6.87, ranking 190 out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status and low operating efficiency. The report highlights that relevant financial data for Quality of Earnings, Operational …
This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals …
The article details the institutional confidence score for aTyr Pharma Inc (ATYR), which is 5.00, placing it 132nd in the Biotechnology & Medical Research industry. It highlights a 24.02% quarter-over-quarter decrease in institutional shareholding proportion to 56.72%. The largest institutional shareholder is James Simons, …
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a passive beneficial ownership of 1,725,072 shares of aTYR PHARMA INC (ATYR) common stock, which represents 1.8% of the class. BlackRock maintains sole voting and dispositive power over these shares. The filing clarifies that while …
This article provides a detailed historical cash flow statement for aTyr Pharma Inc (ATYR), covering quarterly and annual data from FY2013Q4 to FY2026Q1 across operating, investing, and financing activities. It also includes frequently asked questions defining key cash flow metrics and detailing ATYR's specific …
aTyr Pharma, Inc. (NASDAQ: ATYR) generated $190,000 USD in revenue last year, primarily from its Efzofitimod segment. This figure is a decrease from $235,000 USD the previous year, with the United States being the sole contributor to both years' revenues. The article provides a …
aTyr Pharma Ord Shs (LIFE) closed at $18.50, down 2.79%. The company shows strong fundamentals and high growth potential, despite a weak stock market performance over the past month. Analysts rate the stock as "Buy" with a target price of $28.00, suggesting a 47.14% …
aTyr Pharma Inc. (LIFE) is a clinical-stage biotechnology company focused on immune-modulating therapeutics. The company's latest annual results show lower revenue of $0.5 million but a narrowed net loss of $26.0 million, down from $30.0 million previously, indicating progress in cost management. Despite limited …
H.C. Wainwright has reiterated its Hold rating for ATyr Pharma (ATYR.US). This indicates that the analyst firm recommends investors maintain their current position in the stock. The decision reflects the firm's current assessment of the company's financial outlook and market performance.
Search by ticker symbol or company name and select a result to open its chart.